Status:

RECRUITING

Fetal Cerebrovascular Autoregulation in Congenital Heart Disease and Association With Neonatal Neurobehavior

Lead Sponsor:

University of Utah

Collaborating Sponsors:

Primary Children's Hospital

National Heart, Lung, and Blood Institute (NHLBI)

Conditions:

Congenital Heart Disease in Children

Hypoxia

Eligibility:

FEMALE

0-52 years

Phase:

PHASE2

PHASE3

Brief Summary

Determine 1) the impact of abnormal fetal cerebrovascular physiology with neurodevelopmental delay (ND) outcomes and 2) how this relationship is modified by patient and environmental factors such as c...

Detailed Description

Aim 1: Determine the association of baseline cerebrovascular resistance and reactivity and pre-operative neurobehavior in neonates with complex congenital heart disease (CCHD). Exposures: The baseli...

Eligibility Criteria

No eligibility criteria provided.

Key Trial Info

Start Date :

December 17 2021

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 1 2025

Estimated Enrollment :

150 Patients enrolled

Trial Details

Trial ID

NCT05767385

Start Date

December 17 2021

End Date

December 1 2025

Last Update

June 25 2025

Active Locations (5)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (5 locations)

1

University of California San Francisco

San Francisco, California, United States, 94143

2

Children's National Medical Center

Washington D.C., District of Columbia, United States, 20010

3

Maine Medical Center

Scarborough, Maine, United States, 04074

4

Primary Children's Hospital

Salt Lake City, Utah, United States, 84113

Fetal Cerebrovascular Autoregulation in Congenital Heart Disease and Association With Neonatal Neurobehavior | DecenTrialz